Literature DB >> 28668403

F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer.

Rosj Gallicchio1, Anna Nardelli2, Angela Venetucci1, Daniela Capacchione1, Alessandra Pelagalli2, Cesare Sirignano2, Pierpaolo Mainenti2, Piernicola Pedicini1, Giuseppe Guglielmi3, Giovanni Storto4.   

Abstract

OBJECTIVE: We evaluated the prognostic impact of quantitative assessment by maximum standardized uptake value (SUVmax), metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG) on [F-18] FDG PET/CT for patients with peritoneal carcinomatosis from epithelial ovarian cancer (EOC).
METHODS: Thirty-one patients with EOC underwent PET/CT for an early restaging after cytoreductive surgery, having been diagnosed with carcinomatosis (before chemotherapy). The SUVmax, MTV (cm3; 42% threshold) and TLG (g) were registered on residual peritoneal lesions. The patients were followed up 20±12months thereafter. The PET/CT results were compared to overall survival (OS).
RESULTS: The Kaplan-Meier survival analysis for the SUVmax did not reveal significant differences in OS (p=0.48). The MTV survival analysis showed a significant higher OS in patients presenting with a higher tumour burden than those with less tumour burden (p=0.01; 26 vs. 14 months), whereas TLG exhibited a similar trend though not significant (p=0.06). Apart from chemo-resistance, the higher the MTV, the better will be the response to chemotherapy.
CONCLUSIONS: Quantitative assessment by MTV rather than by SUVmax and TLG on PET/CT may be helpful for stratifying patients who present with peritoneal carcinomatosis from EOC, in order to implement the appropriate therapeutic regimen.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carcinomatosis; Epithelial ovarian cancer; PET/CT; Survival

Mesh:

Substances:

Year:  2017        PMID: 28668403     DOI: 10.1016/j.ejrad.2017.05.036

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

Review 1.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

2.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

3.  Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125.

Authors:  Ariel Glickman; Pilar Paredes; Núria Carreras-Diéguez; Aida Niñerola-Baizán; Lydia Gaba; Jaume Pahisa; Pere Fusté; Marta Del Pino; Berta Díaz-Feijóo; Eduardo González-Bosquet; Núria Agustí; Nuria Sánchez-Izquierdo; David Fuster; Andrés Perissinotti; Inmaculada Romero; Esther Fernández-Galán; Josep Lluís Carrasco; Blanca Gil-Ibáñez; Aureli Torné
Journal:  Eur Radiol       Date:  2021-09-29       Impact factor: 7.034

4.  The ability of whole-body SUVmax in F-18 FDG PET/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer.

Authors:  Gun Oh Chong; Shin Young Jeong; Yoon Hee Lee; Hyun Jung Lee; Sang-Woo Lee; Hyung Soo Han; Dae Gy Hong; Yoon Soon Lee
Journal:  J Ovarian Res       Date:  2019-02-04       Impact factor: 4.234

5.  Radiomics Analysis of PET and CT Components of 18F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer.

Authors:  Xihai Wang; Zaiming Lu
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.